The Role of Monocyte Subpopulations in Vascular Injury Following Partial and Transient Depletion

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Specialty Pharmacology

Date 2017 Jun 29

PMID 28656488

Citations 4

Authors

Etty Grad

Ksenia Zolotarevsky

Haim D Danenberg

Mirjam M Nordling-David

Dikla Gutman

Gershon Golomb

Affiliations

Soon will be listed here.

Abstract

The innate immunity system plays a critical role in vascular repair and restenosis development. Liposomes encapsulating bisphosphonates (LipBPs), but not free BPs, suppress neointima formation following vascular injury mediated in part by monocytes. The objective of this study was to elucidate the role of monocyte subpopulations on vascular healing following LipBP treatment. The potency- and dose-dependent treatment effect of clodronate (CLOD) and alendronate (ALN) liposomes on restenosis inhibition, total monocyte depletion, and monocytes subpopulation was studied. Rats subjected to carotid injury were treated by a single IV injection of LipBPs at the time of injury. Low- and high-dose LipALN treatment (3 and 10 mg/kg, respectively) resulted in a dose-dependent effect on restenosis development after 30 days. Both doses of LipALN resulted in a dose-dependent inhibition of restenosis, but only high dose of LipALN depleted monocytes (-60.1 ± 4.4%, 48 h post injury). Although LipCLOD treatment (at an equivalent potency to 3 mg/kg alendronate) significantly reduced monocyte levels (72.1 ± 6%), no restenosis inhibition was observed. The major finding of this study is the correlation found between monocyte subclasses and restenosis inhibition. Non-classical monocyte (NCM) levels were found higher in LipALN-treated rats, but lower in LipCLOD-treated rats, 24 h after injury and treatment. We suggest that the inhibition of circulating monocyte subpopulations is the predominant mechanism by which LipBPs prevent restenosis. The effect of LipBP treatment on the monocyte subpopulation correlates with the dose and potency of LipBPs.

Citing Articles

Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate.

Taoka K, Arai S, Kataoka K, Hosoi M, Miyauchi M, Yamazaki S Sci Rep. 2018; 8(1):15855.

PMID: 30367142 PMC: 6203784. DOI: 10.1038/s41598-018-34193-1.

CD86 Expression by Monocytes Influences an Immunomodulatory Profile in Asymptomatic Patients with Chronic Chagas Disease.

Pinto B, Medeiros N, Teixeira-Carvalho A, Eloi-Santos S, Fontes-Cal T, Rocha D Front Immunol. 2018; 9:454.

PMID: 29599775 PMC: 5857740. DOI: 10.3389/fimmu.2018.00454.

Cardiovascular delivery of drugs and biotherapeutics.

Chorny M, Levy R, Golomb G Drug Deliv Transl Res. 2018; 8(4):865-867.

PMID: 29359245 DOI: 10.1007/s13346-018-0483-y.

Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases.

Aizik G, Grad E, Golomb G Drug Deliv Transl Res. 2017; 8(4):868-882.

PMID: 29058205 DOI: 10.1007/s13346-017-0431-2.

References

Cohen-Sela E, Rosenzweig O, Gao J, Epstein H, Gati I, Reich R . Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. J Control Release. 2006; 113(1):23-30. DOI: 10.1016/j.jconrel.2006.03.010. View

Hansson G . Atherosclerosis--an immune disease: The Anitschkov Lecture 2007. Atherosclerosis. 2008; 202(1):2-10. DOI: 10.1016/j.atherosclerosis.2008.08.039. View

Leuschner F, Dutta P, Gorbatov R, Novobrantseva T, Donahoe J, Courties G . Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol. 2011; 29(11):1005-10. PMC: 3212614. DOI: 10.1038/nbt.1989. View

Strauss-Ayali D, Conrad S, Mosser D . Monocyte subpopulations and their differentiation patterns during infection. J Leukoc Biol. 2007; 82(2):244-52. DOI: 10.1189/jlb.0307191. View

Dijkstra C, Dopp E, van den Berg T, Damoiseaux J . Monoclonal antibodies against rat macrophages. J Immunol Methods. 1994; 174(1-2):21-3. DOI: 10.1016/0022-1759(94)90006-x. View

Afergan E, Epstein H, Dahan R, Koroukhov N, Rohekar K, Danenberg H . Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J Control Release. 2008; 132(2):84-90. DOI: 10.1016/j.jconrel.2008.08.017. View

Epstein H, Gutman D, Cohen-Sela E, Haber E, Elmalak O, Koroukhov N . Preparation of alendronate liposomes for enhanced stability and bioactivity: in vitro and in vivo characterization. AAPS J. 2008; 10(4):505-15. PMC: 2628204. DOI: 10.1208/s12248-008-9060-5. View

Chen L, Shao H, Zhou X, Liu G, Jiang J, Liu Z . Water-mediated cation intercalation of open-framework indium hexacyanoferrate with high voltage and fast kinetics. Nat Commun. 2016; 7:11982. PMC: 4915128. DOI: 10.1038/ncomms11982. View

Ikejima H, Imanishi T, Tsujioka H, Kashiwagi M, Kuroi A, Tanimoto T . Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris. Circ J. 2009; 74(2):337-45. DOI: 10.1253/circj.cj-09-0484. View

10.

Epstein H, Berger V, Levi I, Eisenberg G, Koroukhov N, Gao J . Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats. J Control Release. 2007; 117(3):322-32. DOI: 10.1016/j.jconrel.2006.10.030. View

11.

Yrlid U, Jenkins C, MacPherson G . Relationships between distinct blood monocyte subsets and migrating intestinal lymph dendritic cells in vivo under steady-state conditions. J Immunol. 2006; 176(7):4155-62. DOI: 10.4049/jimmunol.176.7.4155. View

12.

Dal-Secco D, Wang J, Zeng Z, Kolaczkowska E, Wong C, Petri B . A dynamic spectrum of monocytes arising from the in situ reprogramming of CCR2+ monocytes at a site of sterile injury. J Exp Med. 2015; 212(4):447-56. PMC: 4387291. DOI: 10.1084/jem.20141539. View

13.

Zhou X, Liu X, Ji W, Liu J, Guo Z, Ren D . The Kinetics of Circulating Monocyte Subsets and Monocyte-Platelet Aggregates in the Acute Phase of ST-Elevation Myocardial Infarction: Associations with 2-Year Cardiovascular Events. Medicine (Baltimore). 2016; 95(18):e3466. PMC: 4863763. DOI: 10.1097/MD.0000000000003466. View

14.

Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S . Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007; 317(5838):666-70. DOI: 10.1126/science.1142883. View

15.

Danenberg H, Fishbein I, Epstein H, Waltenberger J, Moerman E, Monkkonen J . Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat carotid artery. J Cardiovasc Pharmacol. 2003; 42(5):671-9. DOI: 10.1097/00005344-200311000-00014. View

16.

Haber E, Afergan E, Epstein H, GUTMAN D, Koroukhov N, Ben-David M . Route of administration-dependent anti-inflammatory effect of liposomal alendronate. J Control Release. 2010; 148(2):226-33. DOI: 10.1016/j.jconrel.2010.08.030. View

17.

Lehenkari P, Kellinsalmi M, Napankangas J, Ylitalo K, Monkkonen J, Rogers M . Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002; 61(5):1255-62. DOI: 10.1124/mol.61.5.1255. View

18.

Fazil M, Baboota S, Sahni J, Ameeduzzafar , Ali J . Bisphosphonates: therapeutics potential and recent advances in drug delivery. Drug Deliv. 2014; 22(1):1-9. DOI: 10.3109/10717544.2013.870259. View

19.

Gutman D, Golomb G . Liposomal alendronate for the treatment of restenosis. J Control Release. 2011; 161(2):619-27. DOI: 10.1016/j.jconrel.2011.11.037. View

20.

Toutouzas K, Colombo A, Stefanadis C . Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J. 2004; 25(19):1679-87. DOI: 10.1016/j.ehj.2004.06.011. View